Trial result ·
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This phase 2 trial tested 2 drugs together in mantle cell lymphoma. Everyone had cancer that came back or did not respond. All had at least 2 earlier lines of therapy. That included a BTK inhibitor. 42 people joined. One drug went under the skin. The other went into a vein for 6 cycles.
What they found
The abstract reports high response rates. It also reports high complete remission rates. Median progression-free survival was 18.6 months, with follow-up of 15.9 months. Results were consistent in high-risk groups. Cytokine release syndrome occurred in some people. It was limited to grade 1 and 2 events.
What it means for patients
The authors say the pair gave high complete remission rates. They describe the safety as manageable. They note it was the first such combination study in mantle cell lymphoma.
Why it is not certain yet
Only 42 people took part. There was no comparison group. Follow-up was a median of 15.9 months. The abstract does not say how long responses last after that. An early trial cannot show how the pair compares with other care.
Source
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
PubMed · PMID 42013019We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Mantle cell lymphoma publications